The anti-coagulant drug Pradaxa is associated with a high number of severe bleeding cases that have led to hospitalization, disability, and even death, according to a quarterly report released by the Institute for Safe Medication Practices.
The report, which was released in January and compiled data from the first quarter of 2011, investigated the risk of bleeding events occurring in patients who had been given Pradaxa (Dabigatran). It found that Pradaxa use had been attributed to 505 reported cases of severe bleeding in patients. No other medication the group regularly monitors was linked to as high a number of severe bleeding cases.
The report also found that severe bleeding cases were increasingly common in older patients, and that 25 percent of those who experienced a hemorrhage were at least 84 years old.
Approved by the Food and Drug Administration in October 2010, Pradaxa was thought to be a successor to warfarin as the primary anti-coagulant drug used to help prevent strokes because it had a lower risk of drug interactions. However, the risk of excessive bleeding with Pradaxa is similar to warfarin, and has led to a number of dangerous drug lawsuits since its introduction to the market.
If you or a loved one have taken Pradaxa and suffered uncontrollable bleeding, call Sokolove Law to learn more about how to pursue a dangerous drug lawsuit.
Heart Cholesterol Hypertension